RT Journal Article
SR Electronic
T1 Risk of Incident Cytopenia in Clonal Hematopoiesis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.30.24314665
DO 10.1101/2024.09.30.24314665
A1 Brogan, James
A1 Kishtagari, Ashwin
A1 Corty, Robert W.
A1 Pershad, Yash
A1 Vlasschaert, Caitlyn
A1 Sharber, Brian
A1 Heimlich, J. Brett
A1 Luo, Leo
A1 Xu, Yaomin
A1 Bick, Alexander G.
YR 2024
UL http://medrxiv.org/content/early/2024/10/01/2024.09.30.24314665.abstract
AB Clonal hematopoiesis of indeterminate potential (CHIP) is an asymptomatic condition associated with elevated risk for myeloid neoplasms (MN). Patients with CHIP and cytopenia are at greater risk of MN. Quantifying the incidence of cytopenia and identifying risk factors among CHIP patients is critical for improving clinical management. We analyzed sequencing data from 805,249 participants in the NIH All of Us Research Program (AoU), Vanderbilt’s BioVU repository, and UK Biobank (UKB). Genetic mutations, laboratory values, and MN diagnoses were included in survival analyses to determine predictors of cytopenia in individuals with CHIP and matched controls. The cohort contained 9,374 CHIP cases and 24,749 controls. Cytopenia occurred in 13.5% of cases and 11.6% of controls (HR = 1.17, 95% confidence interval:1.10 – 1.25, P=2.5 × 10−6). Cytopenia risk factors included smoking, male sex, variant allele frequency ≥ 0.20, age ≥ 65, mean corpuscular volume ≥ 100 femtoliters, red cell distribution width ≥ 15%, mutations in high-risk CHIP genes, and ≥ 2 CHIP mutations. In BioVU, 45% of participants with ≥ 4 risk factors progressed to cytopenia within two years. Individuals with CHIP and cytopenia progressed to MN at a rate of ~2% per year, compared to <0.1% per year for those without cytopenia. Longitudinal analysis across three cohorts demonstrated an increased risk of cytopenia in CHIP patients and identified those at highest risk. These findings suggest that cytopenia is a critical step in progression from CHIP to MN, underscoring its utility as an endpoint in cancer prevention trials for CHIP patients.Competing Interest StatementAGB is on the scientific advisory board and has received personal fees from TenSixteen Bio unrelated to the present work.Funding StatementThis work was supported by grants (DP5OD029586, R01AG088657, R01AG083736, P30CA068485) from the National Institutes of Health (NIH), the Burroughs Wellcome Fund Career Award for Medical Scientists, the Edward P. Evans Foundation, the Pew Charitable Trusts and the Alexander and Margaret Stewart Trust, and a Hevolution/AFAR New Investigator Award in Aging Biology and Geroscience Research to AGB. JB was supported by the American Society of Hematology HONORS Award. This research was conducted using the UK Biobank Resource under Application Number 43397. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. BioVU is supported by NIH award UL1 TR002243 from the National Center for Advancing Translational Sciences. The BioVU Whole Genome Sequencing was supported by the Alliance for Genomic Discovery.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Vanderbilt University Medical Center waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.